Vicarious Surgical, Inc. · OTC:RBOT

Vicarious Surgical — Investor Presentation (August 2022)

26 slides from Vicarious Surgical's investor presentation, August 2022

  1. Slide 1: Investor Presentation August 2022

    INVESTOR PRESENTATION AUGUST 2022 VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, yo

  3. Slide 3: Key Investment Highlights

    KEY INVESTMENT HIGHLIGHTS NEXT GENER ATION ROBOTICS ABILITY TO ADDRESS MOST TECHNOLOGY ABDOMINAL PROCEDURES DESIGNED TO SOLVE MANUAL DEVELOPED IN STEALTH BY AND ROBOT-ASSISTED VISIONARY MANAGEMENT TEAM SURGERY SHORTCOMINGS AND INVESTORS TAPPING INTO A $136B MARKET; 96.8% UNADDRESSED BY ROBOTICS 1 [1

  4. Slide 4: Our Team and Investors

    01 OUR TEAM AND INVESTORS VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 4

  5. Slide 5: Visionary Management Team

    VISIONARY MANAGEMENT TEAM CHIEF FINANCIAL OFFICER GENERAL COUNSEL AND VP OF PRODUCT DESIGN AND CHIEF LEGAL OFFICER COMMERCIALIZATION BILL KELLY JUNE MORRIS MICHAEL PRATT CO-FOUNDER, CHIEF VP OF OPERATIONS VP OF STRATEGY AND MEDICAL OFFICER CORPORATE DEVELOPMENT JOHN MAZZOLA BARRY GREENE PETER MEYER

  6. Slide 6: Experienced Board and Advisors, Seasoned Investors

    EXPERIENCED BOARD SEASONED AND ADVISORS INVESTORS SELECT EXISTING INVESTORS EXECUTIVE CHAIRMAN D8 BOARD DIRECTOR­1 BOARD DIRECTOR BOARD DIRECTOR BOARD DIRECTOR DAVID STYKA DAVID HO PHIL LIANG ADAM SACHS RIC FULOP Noted HIV/AIDS Former Operational Researcher; Time “Man of Leader at Auris the Year” 19

  7. Slide 7: The Problem

    02 THE PROBLEM VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 7

  8. Slide 8: The State of Surgery Today

    THE STATE OF SURGERY TODAY TROCAR SIZE VICARIOUS SURGICAL EXISTING SINGLE ROBOTS 4 1.5CM 2.5CM PORT ROBOTS THE BEGINNING ONE STEP FORWARD ONE STEP BACKWARD STUCK AT THE BEGINNING OPEN MINIMALLY- EXISTING OPEN SURGERY INVASIVE SINGLE-PORT SURGERY SURGERY ROBOTS DOMINANCE Manual and Robotic Large inci

  9. Slide 9: Limitations of Robotic Surgery Today

    LIMITATIONS OF ROBOTIC SURGERY TODAY HIGH COST DIFFICULT TO USE LIMITED CAPABILITIES LOW UTILIZATION THESE LIMITATIONS RESULT IN ONLY Capital and service costs Steep learning curves and Ill-suited for many outpatient Large profile, limited portability, 3.2% >$2M investment device-specific training p

  10. Slide 10: Our Solution

    03 OUR SOLUTION VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 10

  11. Slide 11: Our Solution

    VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 03 | OUR SOLUTION 11

  12. Slide 12: The System

    THE SYSTEM 3D SCREEN PROPRIETARY 9 1.5cm 360 SOFTWARE TROCAR SIZE EXISTING SINGLE DEGREES OF SINGLE DEGREES PORT ROBOTS SURGEON VICARIOUS SURGICAL FREEDOM PER ARM INCISION 1 VIEW ROBOT CONSOLE 5-10x 7 1.5CM 1 2.5CM LOWER YEARS CAPITAL COST 2 OF R&D 30+ 34” wide 28 PATIENT CART PATENTS ISSUED FITS TH

  13. Slide 13: Less Invasive While Maximizing Capabilities

    LESS INVASIVE WHILE MAXIMIZING CAPABILITIES INCISION MOTION REACH VISIBILITY MOBILITY ONE 1.5CM 1 TROCAR HUMAN EQUIVALENT ANYWHERE 2 EVERYWHERE 2 PORTABLE VIDEO LINK VIDEO LINK 2 robotic arms and 1 camera through 9 degrees of freedom per arm Unprecedented dexterity through Natural view in any and al

  14. Slide 14: Size

    SIZE Simple, portable, and capable—the Vicarious Surgical robot fits through a standard door and can fit into surgical facilities without construction buildout VICARIOUS SURGICAL ROBOTS LEGACY SURGICAL ROBOTS VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 03 | OUR SOLUTION 14

  15. Slide 15: 360° Reach and View

    360° REACH AND VIEW The Vicarious Surgical robot can work anywhere in the abdomen through a 1.5cm1 incision The 9 decoupled actuators in each arm provide unprecedented dexterity inside of an ultra thin support tube LIMITED L ARGE WORKING WORKING AREA AREA LEGACY SINGLE VICARIOUS PORT ROBOTS SURGICAL

  16. Slide 16: Sensing and Visualization

    SENSING AND VISUALIZATION 3D DEPTH MAPPING FULL MOTION FORCE SENSING TR ACKING + FEEDBACK AT EVERY JOINT 4K HIGH FR AME WIDE FOV AUTOFOCUS R ATE TONE ADJUSTING HEAD MOUNTED LIGHTING DISPL AY 1 [1] WHILE CAPABLE OF HEAD MOUNTED DISPL AY CURRENTLY, HEAD MOUNTED DISPL AY WILL BE 03 | OUR SOLUTION 16 L

  17. Slide 17: Economics

    ECONOMICS Advanced engineering enables sterile portion to be disposable with competitive cost structure • 3D printed and injection molded parts with polymer fiber cables • Decoupled actuators enable polymer cables and parts, lowering part costs vs traditional manufacturing over 5-10x1 • Enables ster

  18. Slide 18: Market Research Features

    MARKET RESEARCH 1| 360º REACH PROVIDES ACCESS TO ENTIRE ABDOMEN FEATURES 2| FULLY ARTICULATING JOINTS ALLOW FOR 9 DEGREES OF FREEDOM Surgeons and administrators reacted positively to the features that our surgical robot provides. Their favorite features are 3| REAL-TIME 4K 3D VISUALIZATION WITH uniq

  19. Slide 19: Market Research Competitor Comparison

    MARKET RESEARCH COMPETITOR COMPARISON 5 | Major Breakthrough VERY EASY SELL Independent blinded study with surgeons and 4.8 hospitals shows over 4 out of 5 score (very easy sell), well above competing solutions 4 | Important Advance STRONG SELLING POSITION COMPARED TO MANUAL MINIMALLY INVASIVE SURGE

  20. Slide 20: Our Pathway to Commercialization

    04 OUR PATHWAY TO COMMERCIALIZATION VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 20

  21. Slide 21: Expected Roadmap

    EXPECTED ROADMAP Initial Manufacturing / Clinical Build Beta 1 Beta 2 Production Build (V1.0) Complete DEVELOPMENT AND REGULATORY Filing FDA ISO 13485 Obtaining NRTL Presubmission Certification FDA De Novo Submission Mark 2021 2022 2023 2024 2025 Launch of Early Center of Excellence Initial Human Us

  22. Slide 22: Center of Excellence Agreements

    CENTER OF EXCELLENCE OUR PARTNERS AGREEMENTS Groundbreaking agreements with TWO WORKING TOGETHER TO REFINE THE PATIENT, SURGEON AND HOSPITAL leading healthcare providers VALUE OF THE VICARIOUS SURGICAL ECOSYSTEM FOR FUTURE STREAMLINED ADOPTION Grants direct access to key stakeholders and invaluable

  23. Slide 23: Our Market, Our Potential

    05 OUR MARKET, OUR POTENTIAL VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022 23

  24. Slide 24: First Indication: Ventral Hernia

    FIRST INDICATION: VENTRAL HERNIA MARKET SIZE 1 EXISTING MEDICARE OUR FUNDAMENTAL ADVANTAGE REIMBURSEMENTS MEDICARE REIMBURSEMENT FOR 0.9M 3.3M EACH PROCEDURE 2 US VENTRAL OUTSIDE US PROCEDURE REIMBURSEMENT RECURRENCE Legacy robots struggle to work on HERNIA VENTRAL HERNIA CASES TYPE RATE CASES the a

  25. Slide 25: Addressable Procedures $136B

    INITIAL ADDRESSABLE ~11.5M 39M MARKET GALLBLADDER ABDOMINAL PROCEDURES 4 PROCEDURES ADDRESSABLE BY (~2.3M US) VICARIOUS 7 ~7.0M ALL OTHER ADDRESSABLE PROCEDURES TOTAL INITIAL HERNIA 3 ADDRESSABLE MARKET $136B (~1.5M US} ~13.4M 6 GI PROCEDURES 5 ~4.1M (~2.8M US) ~2.7M VENTRAL HYSTERECTOMY 2 HERNIA 1

  26. Slide 26: Thank You

    THANK YOU VICARIOUS SURGICAL 78 Fourth Avenue vicarioussurgical.com Waltham, MA, 02451 +1.617.868.1700 VICARIOUS SURGICAL INVESTOR PRESENTATION AUGUST 2022

Vicarious Surgical — Investor Presentation (August 2022) on 6ix